INKON LIFE TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.23 CNY | +1.11% |
|
-4.63% | -22.58% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 1.78B 246M | Sales 2025 * | 2.05B 284M | Capitalization | 5.22B 723M |
|---|---|---|---|---|---|
| Net income 2024 * | 133M 18.41M | Net income 2025 * | 167M 23.12M | EV / Sales 2024 * | 2.94 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.55 x |
| P/E ratio 2024 * |
39.2
x | P/E ratio 2025 * |
32.3
x | Employees | 2,268 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.04% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.11% | ||
| 1 week | -4.63% | ||
| Current month | -0.48% | ||
| 1 month | +13.20% | ||
| 3 months | -5.07% | ||
| 6 months | -20.25% | ||
| Current year | -22.58% |
1 week
8.08
8.58
1 month
7.288.72
Current year
6.5110.74
1 year
6.5113.06
3 years
6.5129.15
5 years
6.5129.71
10 years
4.4529.71
| Managers | Title | Age | Since |
|---|---|---|---|
Wen Peng
CEO | Chief Executive Officer | 56 | 20-03-31 |
Xu Dong Wang
BRD | Director/Board Member | 40 | 19-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Li Xia Tan
CHM | Chairman | 54 | 19-05-22 |
Wen Wen Gong
CHM | Chairman | 44 | 20-09-16 |
Wen Peng
CEO | Chief Executive Officer | 56 | 20-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.87% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 8.23 | +1.11% | 3 959 400 |
| 24-05-16 | 8.14 | -0.97% | 3,398,800 |
| 24-05-15 | 8.22 | -1.08% | 2,862,300 |
| 24-05-14 | 8.31 | -0.36% | 3,656,800 |
| 24-05-13 | 8.34 | -1.88% | 5,266,400 |
End-of-day quote Shenzhen S.E., May 16, 2024
More quotes
INKON Life Technology Co., Ltd., formerly Starmap medicine & technology Co., Ltd., is a China-based company principally engaged in providing medical services. Its medical services focus on cancer prevention, diagnosis, treatment and rehabilitation. The Company is also engaged in the research and development, manufacture and sales of medical equipment, as well as medical software development. Its medical equipment mainly include MASEP digital radiotherapy equipment, MASEP Gamma Knife and other large medical equipment. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
8.23
CNY
Average target price
10.12
CNY
Spread / Average Target
+22.96%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -22.58% | 715M | |
| -18.52% | 16.2B | |
| +5.41% | 12.73B | |
| +3.98% | 11.68B | |
| +4.36% | 10.22B | |
| +28.07% | 8.6B | |
| -4.98% | 7.78B | |
| +6.76% | 6.73B | |
| +7.33% | 6.4B | |
| +48.17% | 4.49B |
- Stock Market
- Equities
- 300143 Stock
